Affimed (AFMD)
(Real Time Quote from BATS)
$3.87 USD
+0.02 (0.52%)
Updated Sep 12, 2024 03:51 PM ET
After-Market: $3.88 +0.01 (0.26%) 4:10 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AFMD 3.87 +0.02(0.52%)
Will AFMD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AFMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AFMD
Affimed Appoints New CEO, Shares Fall on Leadership Change
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates
AFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 Loss, Misses Revenue Estimates
Affimed (AFMD) to Report Q2 Earnings: What's in the Cards?
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for AFMD
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed NV (AFMD) Q2 2024 Earnings Call Transcript Highlights: Financials, Clinical Progress, ...
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed N.V. 2024 Q2 - Results - Earnings Call Presentation
Affimed N.V.: Q2 Earnings Snapshot